Cipher Pharmaceuticals has been growing earnings at an average annual rate of 43%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 0.1% per year. Cipher Pharmaceuticals's return on equity is 16%, and it has net margins of 59.9%.
Key information
43.0%
Earnings growth rate
44.4%
EPS growth rate
Pharmaceuticals Industry Growth
7.3%
Revenue growth rate
-0.1%
Return on equity
16.0%
Net Margin
59.9%
Last Earnings Update
30 Sep 2024
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cipher Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DB:PHE Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Sep 24
26
16
9
0
30 Jun 24
22
23
6
0
31 Mar 24
22
23
6
0
31 Dec 23
21
20
5
0
30 Sep 23
21
32
5
0
30 Jun 23
20
28
5
0
31 Mar 23
20
27
5
0
31 Dec 22
21
27
5
0
30 Sep 22
22
10
5
0
30 Jun 22
21
8
5
0
31 Mar 22
22
9
5
0
31 Dec 21
22
8
5
0
30 Sep 21
22
5
6
0
30 Jun 21
23
6
6
0
31 Mar 21
21
3
6
0
31 Dec 20
22
4
6
0
30 Sep 20
21
7
6
0
30 Jun 20
22
3
5
0
31 Mar 20
23
4
6
0
31 Dec 19
22
3
8
0
30 Sep 19
23
-1
11
0
30 Jun 19
22
2
13
0
31 Mar 19
23
3
14
1
31 Dec 18
23
1
14
1
30 Sep 18
28
6
13
1
30 Jun 18
34
9
13
0
31 Mar 18
37
11
13
0
31 Dec 17
40
11
13
0
30 Sep 17
34
7
13
0
30 Jun 17
32
5
13
0
31 Mar 17
31
1
14
1
31 Dec 16
30
4
16
1
30 Sep 16
33
6
23
1
30 Jun 16
34
2
28
0
31 Mar 16
34
1
29
0
31 Dec 15
34
2
29
1
30 Sep 15
32
3
21
1
30 Jun 15
30
13
14
1
31 Mar 15
30
18
10
1
31 Dec 14
29
19
9
1
30 Sep 14
33
31
7
1
30 Jun 14
32
27
7
1
31 Mar 14
29
25
7
0
31 Dec 13
25
24
6
0
Quality Earnings: PHE has a high level of non-cash earnings.
Growing Profit Margin: PHE's current net profit margins (59.9%) are lower than last year .
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHE has become profitable over the past 5 years, growing earnings by 43% per year.
Accelerating Growth: PHE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PHE had negative earnings growth (-51.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (28.7%).
Return on Equity
High ROE: PHE's Return on Equity (16%) is considered low.